hCFB

Nomenclature

C57BL/6Smoc-Cfbtm1(hCFB)Smoc

Cat. NO.

NM-HU-2000078

Strain State

Repository Live

Export PDF

Gene Summary

Gene Symbol
Cfb

Model Description

The endogenous mouse Cfb gene was replaced by human CFB gene.
Research Application:Immunotherapy,drug screening

Validation Data

image.png

Fig1. Detection of CFB expression in liver by RT-PCR. 

Wild type: only one band at 441 bp with primers F1/R1(mCfb);

Homozygous: only one band at 442 bp with primers F2/R2(hCFB); 

Abbr. M, DNA marker; HO, homozygous; WT, wild type.

image.png

Fig2. Detection of human and mouse CFB expression in serum by ELISA (n=2). 

Abbr. HO, homozygous; WT, wild type.

Note: The mouse CFB ELISA kit cross-reacted with mCFB and humanized CFB.

image.png

Fig3. Detection of hCFB expression in serum by ELISA(n=3/group). 

Abbr. HO, homozygous; WT, wild type

image.png

Fig4. Body Weight(A) and Survival Curve(B) of WT C57BL/6 and HO hCFB mice.

Abbr. HO, homozygous; WT, wild type.

image.png

Fig5. Blood Biochemistry of WT C57BL/6 and HO hCFB mice.

Abbr. HO, homozygous; WT, wild type.

image.png

Fig6. Detection of liver CFB mRNA remaining at Day 7 (A) and serum protein level (B) after single dose of test drug (n=3/group). (Data from a collaborator)

image.png

Fig7.Partial representative pictures of liver and kidney pathology in hCFB knockin mice. No obvious lesions were observed in hCFB knockin mice. 


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more